Merck & Co took a hit on May 14, 2025, as Citigroup downgraded its rating from "Buy" to "Neutral" and slashed its price ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Merck is facing an awkward encore as one of the worst-performing blue chip stocks in 2025, sliding 23.3% year-to-date.

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Merck ...

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at ...

C4 Therapeutics, Inc.’s CCCC share price has surged by 12.77%, which has investors questioning if this is right time to sell.

C4 Therapeutics, Inc.’s CCCC share price has dipped by 7.18%, which has investors questioning if this is right time to buy.

Merck’s stock was gaining after the drugmaker beat quarterly earnings expectations again and maintained its full-year outlook despite additional costs related to tariffs. Photo: Getty Images ...

Since early April, the market has recovered significantly, and she attributed the rally to better-than-expected profit margins and steady corporate performance ... stock that is more promising ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

This strong performance was fueled by consistent sales ... After the earnings announcement on Friday, April 25th, Merck’s (MRK) stock price rose by 4%. However, year-to-date, MRK stock has ...

It operates through two segments, Pharmaceutical and Animal Health. The 52-week range of Merck stock price was $75.93 to $134.63. Merck's dividend yield is 4.06%. It paid $3.24 per share in ...